CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
Montréal, Quebec, Canada and 113 other locations
This study is being done to answer the following question:Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug...
Phase 2
Montreal, Quebec, Canada and 14 other locations
The standard or usual treatment for this disease consists of two chemotherapy drugs gemcitabine and nab-paclitaxel given together.
Phase 2
Montreal, Quebec, Canada and 26 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Montreal, Canada and 203 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Montreal, Quebec, Canada and 195 other locations
and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma...
Phase 3
Montreal, Quebec, Canada and 171 other locations
mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...
Phase 2
Montreal, Quebec, Canada and 44 other locations
unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Why is this study being done? SPOTLIGHT is a new clinical st...
Phase 3
Montreal, Quebec, Canada and 219 other locations
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer age...
Phase 1, Phase 2
Montreal, Quebec, Canada and 48 other locations
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer.
Montréal, Quebec, Canada and 1 other location
Clinical trials
Research sites
Resources
Legal